Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imunon (IMNN) has provided an announcement.
Imunon, Inc. has revealed encouraging results from its Phase 2 OVATION 2 trial, which tested IMNN-001 alongside standard chemotherapy treatments for advanced ovarian cancer. The data indicates that the treatment could potentially extend the median time to event and improve overall survival rates, although statistical significance was not reached. Investors and interested parties are invited to a conference call and can access more information via a webcast or the investor presentation on the company’s website.
For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.